Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity-matched retrospective cohort study of a pan-provincial program in Alberta, Canada.

Gregory FarmerKhokan C SikdarTkt LoJohn ConlyJeremy SlobodanJordan RossSamantha JamesHussain UsmanKyle KempKristi BakerKaren DoucetteCheri Nijssen-JordanLynora M SaxingerA Mark Joffe

Published in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2024)

After adjusting for confounding variables, sotrovimab treatment was not associated with lower odds of a severe outcome within 30-days of COVID-19-positive date.

Keyphrases

coronavirus disease
sars cov
early onset
randomized controlled trial
systematic review
quality improvement
drug induced
combination therapy
adipose tissue
skeletal muscle